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“High-Risk” Aortic Valve Replacement*
Jeffrey J. Popma, MD,y Kamal Khabbaz, MDzS ince the initial description of prosthesis-patient mismatch (PPM) more than 3 decadesago (1), the clinical import of PPM after surgical
aortic valve replacement (SAVR) has been debated in
the surgical published data. The phenotypic manifes-
tation of PPM is an elevated aortic valve gradient after
valve implantation. Although a number of indices
have been used to characterize the frequency of
PPM after valve replacement, the most common
parameter used to describe its magnitude is the effec-
tive oriﬁce area index (EOAi), which accounts for the
body surface area (BSA) and, presumptively, the car-
diac output. PPM is deﬁned as moderate when the
EOAi is #0.85 cm2/m2 but $0.65 cm2/m2, and severe
when the EOAi is <0.65 cm2/m2.
PPM has been associated with higher early (2–5)
and late mortality (4,6–10) after aortic valve sur-
gery. In a meta-analysis comprising 34 studies that
included 27,186 patients and 133,141 patient-years,
both moderate and severe PPM increased all-cause
mortality (hazard ratio: 1.19 and 1.84, respectively)
and cardiac-related mortality (hazard ratio: 1.32 and
6.46, respectively); these relationships were consis-
tent over time (11). The impact of PPM on late
mortality may be inﬂuenced by the presence of
older age, left ventricular (LV) dysfunction, New
York Heart Association functional class III or IV
symptoms, and concomitant coronary artery bypass
grafting (12,13).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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Medtronic Inc.PPM has been associated with a number of other
untoward outcomes, including longer time in the
intensive care unit (3); a reduction in functional
improvement and exercise capacity (14,15); less
regression of LV mass after valve surgery (16,17),
particularly in patients with LV hypertrophy (18);
increased neurologic events (19); and more late
structural valve deterioration (20). PPM may have an
even more profound impact on outcomes in patients
with low gradient aortic stenosis (21,22). PPM was
independently associated with increased rates of
congestive heart failure, impaired LV mass regres-
sion, and a trend toward increased late mortality in
patients with low gradient aortic stenosis (22).
Transcatheter aortic valve replacement (TAVR)
has provided another option for reducing PPM
in patients undergoing aortic valve replacement
because of the lower proﬁle of the transcatheter
valve without a sewing ring (23). A matched analysis
of patients with aortic stenosis compared 50 patients
treated using a balloon-expandable transcatheter
valve with 2 groups of 50 patients who underwent
surgery with a stented valve (Edwards Perimount
Magna, Edwards Lifesciences Corp., Irvine, Cali-
fornia) or a stentless valve (Medtronic Freestyle,
Medtronic Inc., Minneapolis, Minnesota) (23). The
mean transprosthetic gradient at discharge was
lower in the TAVR group (10  4 mm Hg) compared
with the stented (13  5 mm Hg) and stentless (14 
6 mm Hg) surgical groups. The incidence of severe
PPM was signiﬁcantly lower in the TAVR group (6%)
than in the stented (28%) or stentless (20%) surgical
groups, albeit with a higher rate of moderate para-
valvular regurgitation with TAVR (8%) than surgery
(0%) (23).SEE PAGE 1323In this issue of the Journal, Pibarot et al. (24) report
the impact of PPM on late outcomes in 699 patients at
“high risk” for surgery who were randomized to
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1336surgery or TAVR in the PARTNER (Placement of
AoRTic TraNscathetER Valves) trial. Patients in the
TAVR group were exclusively treated with
the balloon-expandable Edwards SAPIEN bio-
prosthesis using transfemoral or transapical access.
Approximately 90% of patients in the surgical group
were treated with an Edwards bovine bioprosthetic
valve by protocol; only 2 patients also underwent a
root enlargement procedure (24). Echocardiograms 7
to 30 days after aortic valve replacement were
reviewed at an independent core laboratory using
echocardiographic criteria for determining PPM,
which is the preferred method compared with in vitro
measurements or calculated oriﬁce area from stan-
dardized tables (6,25).
There are a number of important ﬁndings from
this well-executed analysis. First, the frequencies of
moderate and severe PPM were lower after TAVR
(26.6% and 19.7%, respectively) than after SAVR
(31.9% and 28.1%, respectively) (24), although severe
PPM with TAVR was seen more often than in prior
registry analyses (6%) (23). The differences in severe
PPM between the TAVR and SAVR cohorts were
accentuated in those patients with echocardio-
graphically determined annular diameters <20 mm,
and the rate of PPM was lower in patients who un-
derwent balloon post-deployment dilation, likely
because of further expansion of the transcatheter
valve. It is not clear whether the higher frequency of
severe PPM after TAVR was related to the use of
smaller valve sizes, the independent echocardio-
graphic core laboratory readings, or the large BSA of
patients enrolled in the current study.
Likewise, the 60% frequency of moderate or
severe PPM in the SAVR group in this series was
also slightly higher than the 44.2% aggregate fre-
quency of moderate or severe PPM in a large meta-
analysis (11). These higher rates may be attributable
to the restricted annular sizing (18 to 25 mm) in the
study protocol, although one also wonders whether
the near exclusive (90%) use of a stented bovine
pericardial valve may have inﬂuenced these higher
rates of PPM; surgeons may not have been free
to use “best practice” surgical techniques that
would lower the rate of PPM, including the next
generation of stented (26) and stentless (27) surgical
valves. In addition, given the relationship between
small (19 and 21 mm) surgical valve diameters,
PPM in larger patients, and untoward clinical
outcomes (28–30), one would also ask whether
adjunct surgical root enlargement techniques
would have allowed the use of larger surgical valves
and less PPM had they been permitted by the pro-
tocol (31–33).The second notable ﬁnding of this study is the
relationship involving post-operative PPM, 2-year
mortality, and LV mass regression. The authors sug-
gest that the higher mortality rate may be attributable
to residual LV afterload and failure to normalize
coronary ﬂow reserve after surgery, a plausible
rationale. It is less clear why a similar effect of PPM on
late mortality was not observed in the TAVR group,
and the authors have suggested several cogent rea-
sons. However, in contrast to the current ﬁndings, an
analysis of 165 patients undergoing TAVR, of whom
18.2% patients showed PPM before hospital
discharge, found that patients with PPM had limited
LV mass regression and left atrial volume reduction
over 6 months compared with patients without PPM
(34). Of note, a higher proportion of patients with
PPM did not have improved New York Heart Associ-
ation functional class compared with patients
without PPM (36.7% vs. 1.5%; p < 0.001). PPM may be
a particularly challenging issue for TAVR in patients
with bioprosthetic valve failure (35).
We ﬁnd it interesting that the BSA, body mass in-
dex, and frequency of obesity were all higher in the
patients with PPM in the TAVR group in the current
study. A systematic review of the Society of Thoracic
Surgeons National Cardiac Database that included
42,310 patients found that although effective oriﬁce
area and geometric oriﬁce area were both inversely
correlated with operative mortality, BSA was signiﬁ-
cantly and inversely correlated with operative mor-
tality (36). When patients were stratiﬁed by effective
oriﬁce area, geometric oriﬁce area, or manufacturer’s
labeled valve size and type, BSA elevations were
associated with a decrease rather than an increase in
operative mortality (36). In the current study, the
offsetting reduction in mortality with increased body
weight in patients with PPM and residual moderate–
severe aortic regurgitation adversely affecting out-
comes in patients without PPM may have contributed
to the absence of an association between PPM and late
mortality in the patients undergoing TAVR (37,38).
This is supported by the larger nonrandomized
Continued Access Registry analysis in which a rela-
tionship was shown between PPM and 1-year mortal-
ity in patients without confounding post-procedural
regurgitation (24). One could conclude from these
analyses that PPM is also an important predictor of
late mortality in patients undergoing TAVR, particu-
larly in the absence of post-procedural paravalvular
regurgitation.
Finally, the clinical implications from this study
suggest that the untoward effects of PPM after
surgery in patients with a smaller aortic annulus
are offset by more frequent moderate–severe
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1337paravalvular regurgitation after TAVR, resulting in
similar 2-year mortality rates in the 2 groups (37).
Efforts to reduce paravalvular regurgitation after
TAVR with next-generation devices and improved
valve sizing and implantation techniques may tip this
mortality balance more favorably toward TAVR.
Likewise, advanced surgical methods and next-
generation surgical valves may lessen the frequency
of PPM in high-risk patients undergoing SAVR. Efforts
should continue to minimize PPM for both patientstreated with SAVR and TAVR, because it is likely that
severe PPM will be associated with a continued risk
irrespective of which technique is used for aortic
valve replacement.
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